Lupin gets USFDA tentative nod for anti-bacterial tablets

New Delhi: Drug firm Lupin has received tentative approval from the US health regulator to market its generic anti-bacterial moxifloxacin hydrochloride tablets in the American market. [caption id=“attachment_2359544” align=“alignleft” width=“380”] Reuters[/caption] The company’s US subsidiary, Gavis Pharmaceuticals, has received tentative approval for its moxifloxacin hydrochloride tablets, 400 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE. The approval is to market the company’s product, a generic version of Bayer Healthcare Pharmaceuticals’ Avelox tablets in the same strength, it added. Avelox had US sales of $30.1 million as per IMS MAT June 2016, Lupin said. The stock of Lupin today closed at Rs 1,535.50 on BSE, up 1.28 percent from its previous close.